Ibtrozi (Taletrectinib)

Ibtrozi (taletrectinib) is a kinase inhibitor used for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).

Recommended Dosage:
The recommended dosage of Taletrectinib is 600 mg administered orally once daily on an empty stomach (no food intake at least 2 hours before and 2 hours after taking the dosage) until there is evidence of disease progression or unacceptable toxicity. Take Taletrectinib at approximately the same time each day. Swallow the capsules whole. Do not chew, open, crush, or dissolve the capsule before swallowing.

If any scheduled dose is missed, take the very next dose at its scheduled time on the following day. Avoid food or drink containing grapefruit during treatment with Taletrectinib.

• Monitor liver tests before and during treatment, interrupt Taletrectinib in case AST or ALT increase above 3 times normal with signs and symptoms, or 5 times without. Resume at a reduced dose when values fall. Do not use this drug in serious liver disease because of the life-threatening potential risk of hepatotoxicity overall.
• Patients should report new or worsening cough, fever, or shortness of breath promptly. In case interstitial lung disease or pneumonitis occurs, withhold this treatment and perform necessary imaging. Resume at a lower dose only after confirmed improvement and resolution of signs. Stop permanently for serious cases.
• Obtain ECGs before and during treatment to monitor QTc intervals. Do not use Taletrectinib in those with congenital long QT syndrome or those taking other QT-prolonging medicines. Correct electrolyte imbalances, such as low potassium or magnesium, before starting treatment. Interrupt this treatment for QTc >500 ms until resolution.
• Check serum uric acid levels before starting to take treatment with this drug and periodically thereafter. Start urate-lowering therapy for asymptomatic hyperuricemia in case levels exceed 8 mg/dL. Monitor for gout attacks. Reduce or interrupt the dose if serious hyperuricemia occurs. Maintain adequate hydration to help prevent uric acid accumulation.
• Patients should report weakness, muscle pain, or cramps promptly during treatment. Check creatine phosphokinase levels regularly. Interrupt treatment for serious myalgia with marked CPK elevations above 5 times normal. Resume at a reduced dose when symptoms resolve and CPK normalizes.
• Assess fracture risk before starting this treatment, especially in those with osteoporosis or bone metastases. Consider weight-bearing exercise, calcium, and vitamin D supplementation. Monitor for new bone pain or fractures during treatment. Stop using treatment and refer to orthopedics for serious or multiple skeletal fractures that require intervention.
• Women of childbearing potential should use appropriate contraception during this treatment and for at least 3 months after the final dose. Discuss potential risks to a fetus. If pregnancy occurs, discontinue medicine immediately and monitor the mother and baby closely for adverse outcomes and developmental effects.
• Because this drug may pass into human breast milk and harm the nursing infant, women should not breastfeed during treatment and for at least 30 days after the final dose. Discuss alternative feeding options. If urgent, monitor the infant for potential toxicity and consult pediatrics before resuming breastfeeding.

What documents are required to import IBTROZI to India?

IBTROZI (taletrectinib) capsules can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is IBTROZI available in India?

IBTROZI (Taletrectinib capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On availability of Ibtrozi in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

IBTROZI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of IBTROZI (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork-in-253190.hostingersite.com for Ibtrozi 200 mg Capsule price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source IBTROZI (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ibtrozi®?

Taletrectinib is the Generic Name for the trade name drug Ibtrozi®.

What is the Manufacturer’s Name of Ibtrozi®?

Ibtrozi® is manufactured by Nuvation Bio Inc.

Is Ibtrozi® approved by the FDA?

Yes. Ibtrozi® approved by the FDA. Date of initial approval: June 11, 2025.

What is the dosage and form of Ibtrozi® supplied?

Ibtrozi is supplied in Capsules: 200 mg of Taletrectinib for oral administration.

What are the most common side effects of Ibtrozi® 200 mg Capsule?

The most common side effects of Ibtrozi® are diarrhea, dizziness, rash, nausea, vomiting, constipation, and fatigue.

How much does Ibtrozi® 200 mg Capsule cost in India?

Ibtrozi® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Prices of Ibtrozi Capsules may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Ibtrozi 200 mg cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork-in-253190.hostingersite.com.

Can Ibtrozi® 200 mg Capsules be available in SAARC countries?

Apart from Gulf countries, Ibtrozi® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Ibtrozi® capsules in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Ibtrozi® 200 mg Capsules online in India?

Yes, one can buy Ibtrozi 200 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Ibtrozi® Capsule through legal channels.

What are the storage conditions of Ibtrozi® 200 mg Capsules?

Store Taletrectinib oral capsules at 20°C to 25°C (68°F to 77°F); excursions are permitted to 15°C to 30°C (59°F to 86°F).